» Articles » PMID: 30375266

Regeneration of a Bioengineered Thyroid Using Decellularized Thyroid Matrix

Overview
Journal Thyroid
Date 2018 Oct 31
PMID 30375266
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hypothyroidism is a common hormone deficiency condition. Regenerative medicine approaches, such as a bioengineered thyroid, have been proposed as potential therapeutic alternatives for patients with hypothyroidism. This study demonstrates a novel approach to generate thyroid grafts using decellularized rat thyroid matrix.

Methods: Isolated rat thyroid glands were perfused with 1% sodium dodecyl sulfate to generate a decellularized thyroid scaffold. The rat thyroid scaffold was then recellularized with rat thyroid cell line to reconstruct the thyroid by perfusion seeding technique. As a pilot study, the decellularized rat thyroid scaffold was perfused with human-derived thyrocytes and parathyroid cells.

Results: The decellularization process retained the intricate three-dimensional microarchitecture with a perfusable vascular network and native extracellular matrix components, allowing efficient reseeding of the thyroid matrix with the FRTL-5 rat thyroid cell line generating three-dimensional follicular structures in vitro. In addition, the recellularized thyroid showed successful cellular engraftment and thyroid-specific function, including synthesis of thyroglobulin and thyroid peroxidase. Moreover, the decellularized rat thyroid scaffold could further be recellularized with human-derived thyroid cells and parathyroid cells to reconstruct a humanized bioartificial endocrine organ, which maintained expression of critical genes such as thyroglobulin, thyroid peroxidase, and parathyroid hormone.

Conclusion: These findings demonstrate the utility of a decellularized thyroid extracellular matrix scaffold system for the development of functional, bioengineered thyroid tissue, which could potentially be used to treat hypothyroidism.

Citing Articles

Engineering a functional thyroid as a potential therapeutic substitute for hypothyroidism treatment: A systematic review.

Li L, Sheng Q, Zeng H, Li W, Wang Q, Ma G Front Endocrinol (Lausanne). 2022; 13:1065410.

PMID: 36531472 PMC: 9755335. DOI: 10.3389/fendo.2022.1065410.


From hormone replacement therapy to regenerative scaffolds: A review of current and novel primary hypothyroidism therapeutics.

Heim M, Nixon I, Emmerson E, Callanan A Front Endocrinol (Lausanne). 2022; 13:997288.

PMID: 36277721 PMC: 9581390. DOI: 10.3389/fendo.2022.997288.


Stem Cell Therapy for Thyroid Diseases: Progress and Challenges.

Ye S, Zhu Z Curr Ther Res Clin Exp. 2022; 96:100665.

PMID: 35371349 PMC: 8968462. DOI: 10.1016/j.curtheres.2022.100665.


Exploring Somatic Alteration Associating With Aggressive Behaviors of Papillary Thyroid Carcinomas by Targeted Sequencing.

Li Y, Gao W, Cai X, Jin A, Shen J, Zhang Y Front Oncol. 2021; 11:722814.

PMID: 34692499 PMC: 8529196. DOI: 10.3389/fonc.2021.722814.


Employing Extracellular Matrix-Based Tissue Engineering Strategies for Age-Dependent Tissue Degenerations.

Jo Y, Hwang S, Jang J Int J Mol Sci. 2021; 22(17).

PMID: 34502277 PMC: 8431718. DOI: 10.3390/ijms22179367.